Fasting insulin: difference between revisions
Diff·revision 4 → 5·16:02, 26 Oct 2024
Difference between revision 4 and revision 5 of Fasting insulin. 3 lines changed; the page grew by 380 bytes.
| Revision 4 — 00:41, 6 Oct 2024 DEXA_Dilys (talk) expand §Standardisation 1,662 bytes ±0 | Revision 5 — 16:02, 26 Oct 2024 LipidLedgerLou (talk) clarify that the units differ between the two cited papers 2,042 bytes +380 | ||
|---|---|---|---|
| 10 | Insulin immunoassays are poorly standardised between manufacturers, differing in cross-reactivity with proinsulin and its split products. Values from different laboratories are not interchangeable, and derived indices inherit the discrepancy.{{r|wallace2004}} | 10 | Insulin immunoassays are poorly standardised between manufacturers, differing in cross-reactivity with proinsulin and its split products. Values from different laboratories are not interchangeable, and derived indices inherit the discrepancy.{{r|wallace2004}} |
| 11 | 11 | ||
| + | 12 | Its principal use is as an input to derived indices, chiefly [[HOMA-IR|HOMA-IR]] and HOMA-B, which combine it with fasting glucose to estimate insulin resistance and secretory capacity respectively.{{r|matthews1985}} | |
| + | 13 | ||
| 12 | == Why it needs glucose alongside it == | 14 | == Why it needs glucose alongside it == |
| 13 | Insulin secretion is a response to glucose. A high fasting insulin with a normal fasting glucose indicates that normal glucose is being maintained at the cost of high insulin — the signature of insulin resistance with preserved secretion. The same insulin with a high glucose indicates resistance with inadequate compensation.{{r|wallace2004}} | 15 | Insulin secretion is a response to glucose. A high fasting insulin with a normal fasting glucose indicates that normal glucose is being maintained at the cost of high insulin — the signature of insulin resistance with preserved secretion. The same insulin with a high glucose indicates resistance with inadequate compensation.{{r|wallace2004}} |
| ⋮ | ⋮ | ||
| 18 | {{reflist}} | 20 | {{reflist}} |
| 19 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> | 21 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> |
| + | 22 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> | |
| 20 | 23 | ||
| 21 | {{DEFAULTSORT:Fasting insulin}} | 24 | {{DEFAULTSORT:Fasting insulin}} |